The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's ...

An anemia drug developed under an alliance between FibroGen ... where it is currently under regulatory review as a treatment for chemotherapy-induced anemia. AstraZeneca’s partnership with ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...

The Chemotherapy Induced Anemia market reached a value of USD 1,309.4 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,800.2 Million by 2035, exhibiting a growth rate (CAGR ...

Add videos to your saved list and come back to them any time.

Different steroid regimens in the treatment of warm autoimmune hemolytic anemia were comparable concerning their safety profile, so parental regimes are used as rescue treatment (10). In drug-induced ...